公司业务定位 - 全球生物制药公司专注于高未满足医疗需求疗法的发现、开发和商业化 [1] 核心产品进展 - 旗舰产品Sephience获美国和欧洲批准用于治疗儿童及成人PKU患者 [1] - 该产品将成为公司未来增长的基础性产品 [1] 财务资源状况 - 第二季度末资产负债表现金余额超过19亿美元 [1] - 现金储备可支撑公司实现近期现金流盈亏平衡 [2] - 具备业务拓展资金实力以补充商业和研发产品组合 [2] 战略发展态势 - 过去1-2年重点推进公司转型并为未来建设基础 [1] - 当前进入以基础产品驱动的新增长阶段 [2] - 产品具备强劲的大规模收入潜力 [2]

PresentationWe have Matt and Pierre for a fireside chat. I usually like to give you guys some time just for quick intros overall setup. Again, PTC has been changed substantially over the last 18 months, 2 years. So yes, if you can give like the brief intro and then again, a detailed discussion on Sephience and some aspects of the business.All right. Thanks, everyone, for joining us. I'm Tiago Fauth. I'm a biotech analyst here at Wells Fargo. We have PTC Therapeutics joining us at our health care conference ...